Foghorn Therapeutics Inc.

NASDAQ:FHTX

Biotechnology

Healthcare
$1.79 +2.35%

+$0.10 today

Market cap
$107.33M
Beta
2.89
P/E (TTM)
-3.8
EPS (TTM)
-$1.08
52W Low $3.27High $6.95

Volume 0.53M

Average 0.15M

FHTX Short-term Investments

Marketable securities and deposits the company expects to convert to cash within a year.

Foghorn Therapeutics Inc.NASDAQ: FHTX

Short-term Investments · Q1 FY2026 · quarter ended Mar 2026

Short-term investments falls 39.9% from a year ago

Short-term investments stood at $95.97M at the end of Q1 FY2026, down 39.9% from a year earlier and up 23.0% from the prior quarter. Over 3 fiscal years it compounded at -35.7% a year.

Context

  • Short-term investments amounted to 43.2% of total assets at the end of Q1 FY2026, down 18.5 pp from a year earlier.
  • Short-term investments increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether short-term investments keeps falling in the next quarterly balance sheet after a -39.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$95.97M+23.0% QoQ
Last fiscal yearDec 2025
$78.02M-58.6% YoY
Year agoMar 2025
$159.56M-39.9% since
Short-term Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-39.9%——
1 year-58.6%——
3-year CAGR-35.7%——
5-year CAGR——
10-year CAGR——

Short-term Investments history

USD · from the balance sheet

Latest · FY2025
78.02M USD
Year-over-year change
-58.6%
4-year CAGR
+10.1%

Short-term Investments vs competitors

How FHTX compares with its peers on the latest reported figures

  • FHTX's Mar 2026 short-term investments of $95.97M is the 6th highest of the 11 companies compared; the peer median is $88.64M.
  • Its year-over-year change of -39.9% is the 5th highest of 7, against a peer median of -25.1%.
  • Short-term investments amounts to 43.2% of total assets for FHTX, versus a peer median of 37.6%.
FHTX Competitors Peer median
Short-term Investments for FHTX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ASMBAssembly Biosciences, Inc.Mar 2026$195.48M +189.1%+69.1%83.0%
TRDAEntrada Therapeutics, Inc.Mar 2026$178.42M -43.3%+12.7%53.2%
VNDAVanda Pharmaceuticals Inc.Mar 2026$148.28M -35.3%-18.6%34.2%
ENTAEnanta Pharmaceuticals, Inc.Mar 2026$128.85M -3.2%-8.6%40.9%
IMRXImmuneering CorporationMar 2026$109.37M —+10.3%0.1%
FHTXFoghorn Therapeutics Inc.Mar 2026$95.97M -39.9%-35.7%43.2%
SGMTSagimet Biosciences Inc.Mar 2026$67.91M -15.0%+34.4%63.0%
PYXSPyxis Oncology, Inc.Mar 2026$35.25M -62.0%—54.8%
ARCTArcturus Therapeutics Holdings Inc.Mar 2026$0 ——0.0%
HUMAHumacyte, Inc.Mar 2026$0 ——0.0%
ZURAZura Bio LimitedMar 2026$0 ——0.0%
Peer median (excluding FHTX) $88.64M-25.1%+11.5%37.6%

Competitors are the stored peer set for FHTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents101.14M52.21M80.34M55.45M80.88M
Short-term Investments53.15M293.58M153.72M188.29M78.02M
Net Receivables300M0000
Inventory00000
Other Current Assets05.6M6.12M5.85M4.34M
Total Current Assets459.56M351.4M240.18M249.6M163.24M
Property, Plant & Equipment (Net)56.08M49.4M42.91M32.61M32.86M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets4.13M4.09M2.82M1.78M2M
Total Non-current Assets60.21M53.48M45.74M34.38M34.87M
Total Assets519.77M404.88M285.92M283.98M198.1M
Account Payables3.82M5.41M6.26M3.79M4.27M
Short-term Debt00000
Tax Payables00674K00
Deferred Revenue28.32M32.82M34.55M45.61M43.19M
Other Current Liabilities5.99M5.06M4.38M4.74M6.32M
Total Current Liabilities48.69M55.21M58.44M66.99M59.74M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)322.73M304M268.12M234.46M205.96M
Other Non-current Liabilities143K29K00556K
Total Non-current Liabilities374.21M349.57M304.67M262.52M246.87M
Total Liabilities422.9M404.77M363.11M329.51M306.6M
Common Stock4K4K4K6K6K
Retained Earnings(264.26M)(373.14M)(471.56M)(558.18M)(632.47M)
Accumulated OCI(10K)(3.99M)(826K)135K24K
Other Stockholders Equity00000
Minority Interest00000
Total Equity96.87M112K(77.19M)(45.53M)(108.5M)
Total Debt58.33M51.51M45.07M37.13M41.27M
Net Debt(42.8M)(707K)(35.26M)(18.32M)(39.61M)

Foghorn Therapeutics Inc.

NASDAQ:FHTX

Intrinsic Alpha fair value

Locked

Current Price

$1.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.